

Activity Outline
Topics in Public Health: President's Emergency Plan for AIDS Relief (PEPFAR) – The Basics
December 13, 2019
Webinar

Activity Coordinator
Ashlee Januszewicz
Ashlee.Januszewicz@fda.hhs.gov

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

The goal of this seminar is to educate the audiences to have a better understanding of the importance of the PEPFAR program (the US President's Emergency Plan For AIDS Relief known as PEPFAR is a government initiative to help save the lives of those suffering from HIV / AIDS), its goals, and how generic drugs are approved and handled for products listed under this program, in which providing HIV meds around the world saving over 11.5 million lives with HIV & reducing 96% transmission to partners.

References

- Chahal HS, Murray JS, Shimer M, Capella P, Presto R, Valdez ML, Lurie PG. The US Food and Drug Administration's tentative approval process and the global fight against HIV. J Int AIDS Soc. 2017 Dec; 20(4).
- U.S. State Department. The United States President's Emergency Plan for AIDS Relief. [cited 2019 Oct 7]. Available from: <https://www.state.gov/pepfar/>.

Series Objectives

- Describe scientific evidence supporting the HHS Initiatives, Surgeon General Priorities or any other public health concern
- Explain the multi-disciplinary approach in addressing public health issues
- Identify public health concerns.
- Identify ways Public Health Professionals can impact public health issues.

Learning Objectives After completion of this activity, the participant will be able to:

- Describe the PEPFAR program and how the program is running.
- Summarize the process by which FDA's Office of Generic Drugs (OGD) approves medications under this program.

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health.

Agenda

Lecture 1 December 13, 2019

Time	Topic	Speaker
2:00 - 3:00 PM	President's Emergency Plan for AIDS Relief (PEPFAR) – The Basics	Tina Nhu, PharmD, R. Ph

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-19-014-L04-P, and ACPE Universal Activity Number JA0002895-0000-19-014-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- Nhu, Tina, PharmD, R. Ph, pharmacist, fda - nothing to disclose

Planning Committee

- Alu, Susan, Pharm.D., Clinical Pharmacist, U.S. Public Health Service - nothing to disclose
- Begansky, Stephanie, PharmD, , BCACP, Advanced Clinical Pharmacist, IHS - nothing to disclose
- Birch-Smith, Postelle, PharmD - nothing to disclose
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
- CHIN, EDWARD, Medical Officer, DNDP - nothing to disclose

- ▣ Camilli, Sara, PharmD, , BCPS, Associate Director, FDA/CDER/OSE/DPV II - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Janusiewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - nothing to disclose
- ▣ La, Thang, PharmD, MPH, Central Triage Unit Manager, FDA/CDER/OSE/RSS - nothing to disclose
- ▣ Leung, Tamy, PharmD, MPH, BCPS, Accountable Care Organization Coordinator, Centers for Medicare and Medicaid - nothing to disclose
- ▣ Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - nothing to disclose
- ▣ McClain, Rena, PharmD, CMS - nothing to disclose
- ▣ Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - nothing to disclose
- ▣ Wagner, Lindsay, PharmD, Team Leader, FDA - nothing to disclose
- ▣ khatri, Sadhna, PharmD, MPH, MS, MEd, Regulatory Officer, FDA/CDER/OCD/PASE - nothing to disclose

CE Consultation and Accreditation Team

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.